Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease
暂无分享,去创建一个
Dalong Zhu | Y. Bi | S. Shen | W. Feng | Ping Li | Tingting Yin | Caixia Gao | Wei Chen | Min Wu
[1] J. Holst,et al. Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference , 2016, Diabetes Care.
[2] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[3] Farhad Zamani,et al. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. , 2016, World journal of gastroenterology.
[4] H. Bian,et al. I148M variant of PNPLA3 increases the susceptibility to non‐alcoholic fatty liver disease caused by obesity and metabolic disorders , 2016, Alimentary pharmacology & therapeutics.
[5] Rachel M. Brown,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.
[6] Qianyue Xu,et al. Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studies , 2016, Diabetes/metabolism research and reviews.
[7] W. Wahli,et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.
[8] A. Marcadenti,et al. Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease , 2015, Journal of diabetes research.
[9] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[10] Xin Gao,et al. Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases , 2015, Obesity.
[11] Dongfeng Chen,et al. Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study , 2015, Clinics.
[12] A. Ido,et al. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies , 2015, Clinical Journal of Gastroenterology.
[13] E. Kang,et al. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway , 2015, Autophagy.
[14] J. Lavine,et al. Review article: the management of paediatric nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.
[15] M. Hao,et al. Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes , 2014, Diabetes/metabolism research and reviews.
[16] Ming Li,et al. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes , 2014, Acta Diabetologica.
[17] S. Alavian,et al. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. , 2014, Nutrition.
[18] S. Reeder,et al. Quantitative chemical shift‐encoded MRI is an accurate method to quantify hepatic steatosis , 2014, Journal of magnetic resonance imaging : JMRI.
[19] R. Scholten,et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta‐analysis , 2014, Diabetes/metabolism research and reviews.
[20] K. Cusi,et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.
[21] T. Saibara,et al. Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease , 2013, PloS one.
[22] Rohit Loomba,et al. The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.
[23] Jiang He,et al. Prevalence and control of diabetes in Chinese adults. , 2013, JAMA.
[24] Christopher D Byrne,et al. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. , 2013, The Journal of clinical endocrinology and metabolism.
[25] Hiroki Sato,et al. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. , 2013, Internal medicine.
[26] Meng-Su Zeng,et al. Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method , 2011, Obesity.
[27] Christopher D. Williams,et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.
[28] P. Hayes,et al. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.
[29] N. Chalasani,et al. Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series , 2010, The American Journal of Gastroenterology.
[30] Corby K. Martin,et al. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. , 2010, Journal of diabetes and its complications.
[31] G. Cowin,et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. , 2009, Journal of hepatology.
[32] T. Ueno,et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. , 2005, Hepato-gastroenterology.
[33] S. Pattingre,et al. The Evolutionarily Conserved Domain of Beclin 1 is Required for Vps34 Binding, Autophagy, and Tumor Suppressor Function , 2005, Autophagy.
[34] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[35] M. Dumont,et al. European Association for the Study of the Liver , 1971 .